The DOI matches its Crossref record; 142 of the 142 references it cites were found in a registry or an index.
Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies
Open accessAbstract
With the broad application of cancer immunotherapies such as immune checkpoint inhibitors in multiple cancer types, the immunological landscape in the tumor microenvironment (TME) has become enormously important for determining the optimal cancer treatment. Tumors can be immunologically divided into two categories: inflamed and non-inflamed based on the extent of immune cell infiltration and their activation status. In general, immunotherapies are preferable for the inflamed tumors than for non-inflamed tumors. Regulatory T cells (Tregs), an immunosuppressive subset of CD4+ T cells, play an essential role in maintaining self-tolerance and immunological homeostasis. In tumor immunity, Tregs compromise immune surveillance against cancer in healthy individuals and impair the antitumor immune response in tumor-bearing hosts. Tregs, therefore, accelerate immune evasion by tumor cells, leading to tumor development and progression in various types of cancer. Therefore, Tregs are considered to be a crucial therapeutic target for cancer immunotherapy. Abundant Tregs are observed in the TME in many types of cancer, both in inflamed and non-inflamed tumors. Diverse mechanisms of Treg accumulation, activation, and survival in the TME have been uncovered for different tumor types, indicating the importance of understanding the mechanism of Treg infiltration in each patient when selecting the optimal Treg-targeted therapy. Here, we review recent advances in the understanding of mechanisms leading to Treg abundance in the TME to optimize Treg-targeted therapy. Furthermore, in addition to the conventional strategies targeting cell surface molecules predominantly expressed by Tregs, reagents targeting molecules and signaling pathways specifically employed by Tregs for infiltration, activation, and survival in each tumor type are illustrated as novel Treg-targeted therapies. The effectiveness of immune precision therapy depends on conditions in the TME of each cancer patient.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Regulatory T Cells and Immune Tolerance
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,325
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Chen, W., Jin, W., Hardegen, N., Lei, K.-J., Li, L., Marinos, N., McGrady, G., & Wahl, S. M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030152 · Cited by 4,699
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
Zhang, L., Xu, J., Zhang, X., Zhang, Y., Wang, L., Huang, X., & Xu, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479442 · Cited by 4,088
An essential role for Scurfin in CD4+CD25+ T regulatory cells
Khattri, R., Cox, T., Yasayko, S.-A., & Ramsdell, F. (2003) · Nature Immunology · doi:10.1038/ni909 · Cited by 2,856
Deaglio, S., Dwyer, K. M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J.-F., Enjyoji, K., Linden, J., Oukka, M., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062512 · Cited by 2,470
Miyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.019 · Cited by 2,291
The Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence
Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3958 · Cited by 2,144 · cited 1×
“On the other hand, treatments such as radiation therapy 103 and CTLA-4 blocking antibodies 104 promote the accumulation of Tregs in tumors, which is considered an adaptive immune resistance mechanism.”
BackgroundReciprocal T H 17 and Regulatory T Cell Differentiation Mediated by Retinoic Acid
Mucida, D., Park, Y., Kim, G., Turovskaya, O., Scott, I., Kronenberg, M., & Cheroutre, H. (2007) · Science · doi:10.1126/science.1145697 · Cited by 1,982 · cited 1×
“18 In contrast to tTregs, pTregs are unstable and convert to conventional FOXP3 − CD4 + T cells (Tconvs) with the loss of FOXP3 expression.”
BackgroundTertiary lymphoid structures in the era of cancer immunotherapy
Sautès-Fridman, C., Petitprez, F., Calderaro, J., & Fridman, W. H. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0144-6 · Cited by 1,884
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860
Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance
Shimizu, J., Yamazaki, S., Takahashi, T., Ishida, Y., & Sakaguchi, S. (2002) · Nature Immunology · doi:10.1038/ni759 · Cited by 1,729
Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
Costa, A., Kieffer, Y., Scholer-Dahirel, A., Pelon, F., Bourachot, B., Cardon, M., Sirven, P., Magagna, I., Fuhrmann, L., Bernard, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.011 · Cited by 1,705 · cited 1×
“Because Fc γ RIIB can be induced in activated CD8 + T cells in the TME, FGL2 secreted by Tregs binds to Fc γ RIIB in CD8 + T cells and leads to their apoptosis through caspase 3 and 7 induction.”
BackgroundSpranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
Mezrich, J. D., Fechner, J. H., Zhang, X., Johnson, B. P., Burlingham, W. J., & Bradfield, C. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903670 · Cited by 1,601
Regulatory T Cell-Derived Interleukin-10 Limits Inflammation at Environmental Interfaces
Rubtsov, Y. P., Rasmussen, J. P., Chi, E. Y., Fontenot, J., Castelli, L., Ye, X., Treuting, P., Siewe, L., Roers, A., Henderson, W. R., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.017 · Cited by 1,586 · cited 1×
“44 Although IL-10 exerts various effects in the TME, its immuno-suppressive effect can be enhanced with IL-35, which is also produced by Tregs.”
BackgroundSimpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472 · cited 2×
“110 In humans, while Treg depletion was not mainly involved in antitumor efficacy by ipilimumab, 104 111 potential contribution of Fc- mediated ADCC was shown.”
BackgroundTumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376
Borsellino, G., Kleinewietfeld, M., Di Mitri, D., Sternjak, A., Diamantini, A., Giometto, R., Höpner, S., Centonze, D., Bernardi, G., Dell'Acqua, M. L., et al. (2007) · Blood · doi:10.1182/blood-2006-12-064527 · Cited by 1,286
Pandiyan, P., Zheng, L., Ishihara, S., Reed, J., & Lenardo, M. J. (2007) · Nature Immunology · doi:10.1038/ni1536 · Cited by 1,286
Metabolic support of tumour-infiltrating regulatory T cells by lactic acid
Watson, M. J., Vignali, P. D. A., Mullett, S. J., Overacre-Delgoffe, A. E., Peralta, R. M., Grebinoski, S., Menk, A. V., Rittenhouse, N. L., DePeaux, K., Whetstone, R. D., et al. (2021) · Nature · doi:10.1038/s41586-020-03045-2 · Cited by 1,259
Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments
Angelin, A., Gil-de-Gómez, L., Dahiya, S., Jiao, J., Guo, L., Levine, M. H., Wang, Z., Quinn, W. J., Kopinski, P. K., Wang, L., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.12.018 · Cited by 1,246
Setoguchi, R., Hori, S., Takahashi, T., & Sakaguchi, S. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041982 · Cited by 1,235
Metabolic Instruction of Immunity
Buck, M. D., Sowell, R. T., Kaech, S. M., & Pearce, E. L. (2017) · Cell · doi:10.1016/j.cell.2017.04.004 · Cited by 1,214
FOXP3 Controls Regulatory T Cell Function through Cooperation with NFAT
Wu, Y., Borde, M., Heissmeyer, V., Feuerer, M., Lapan, A. D., Stroud, J. C., Bates, D. L., Guo, L., Han, A., Ziegler, S. F., et al. (2006) · Cell · doi:10.1016/j.cell.2006.05.042 · Cited by 1,189
Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate
Zheng, Y., Josefowicz, S., Chaudhry, A., Peng, X. P., Forbush, K., & Rudensky, A. Y. (2010) · Nature · doi:10.1038/nature08750 · Cited by 1,169
Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T., & Nakayama, E. (1999) · PubMed · Cited by 1,062
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
Jiang, H., Hegde, S., Knolhoff, B. L., Zhu, Y., Herndon, J. M., Meyer, M. A., Nywening, T. M., Hawkins, W. G., Shapiro, I. M., Weaver, D. T., et al. (2016) · Nature Medicine · doi:10.1038/nm.4123 · Cited by 1,060
Natural and Adaptive Foxp3+ Regulatory T Cells: More of the Same or a Division of Labor?
Curotto de Lafaille, M. A., & Lafaille, J. J. (2009) · Immunity · doi:10.1016/j.immuni.2009.05.002 · Cited by 1,055
Granzyme B and Perforin Are Important for Regulatory T Cell-Mediated Suppression of Tumor Clearance
Cao, X., Cai, S. F., Fehniger, T. A., Song, J., Collins, L. I., Piwnica-Worms, D. R., & Ley, T. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.08.014 · Cited by 1,035
Moran, A. E., Holzapfel, K. L., Xing, Y., Cunningham, N. R., Maltzman, J. S., Punt, J., & Hogquist, K. A. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110308 · Cited by 1,034
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
Kamada, T., Togashi, Y., Tay, C., Ha, D., Sasaki, A., Nakamura, Y., Sato, E., Fukuoka, S., Tada, Y., Tanaka, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1822001116 · Cited by 1,008
Self-citationTGF-β1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells
Marie, J. C., Letterio, J. J., Gavin, M., & Rudensky, A. Y. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042276 · Cited by 985
Regulatory T cells in tumor immunity
Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944
Self-citationThe polarization of immune cells in the tumour environment by TGFβ
Flavell, R. A., Sanjabi, S., Wrzesinski, S. H., & Licona-Limón, P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2808 · Cited by 940
The ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017) · Immunological Reviews · doi:10.1111/imr.12528 · Cited by 927
Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer.
Kieffer, Y., Hocine, H. R., Gentric, G., Pelon, F., Bernard, C., Bourachot, B., Lameiras, S., Albergante, L., Bonneau, C., Guyard, A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1384 · Cited by 910
An essential role for the IL-2 receptor in Treg cell function
Chinen, T., Kannan, A. K., Levine, A. G., Fan, X., Klein, U., Zheng, Y., Gasteiger, G., Feng, Y., Fontenot, J. D., & Rudensky, A. Y. (2016) · Nature Immunology · doi:10.1038/ni.3540 · Cited by 888
Inflammatory microenvironment remodelling by tumour cells after radiotherapy
McLaughlin, M., Patin, E. C., Pedersen, M., Wilkins, A., Dillon, M. T., Melcher, A. A., & Harrington, K. J. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0246-1 · Cited by 883
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. (2016) · Nature Medicine · doi:10.1038/nm.4086 · Cited by 871
Self-citationTh17 cells transdifferentiate into regulatory T cells during resolution of inflammation
Gagliani, N., Vesely, M. C. A., Iseppon, A., Brockmann, L., Xu, H., Palm, N. W., de Zoete, M. R., Licona-Limón, P., Paiva, R. S., Ching, T., et al. (2015) · Nature · doi:10.1038/nature14452 · Cited by 802
Kumagai, S., Togashi, Y., Kamada, T., Sugiyama, E., Nishinakamura, H., Takeuchi, Y., Vitaly, K., Itahashi, K., Maeda, Y., Matsui, S., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0769-3 · Cited by 783
Self-citationGobert, M., Treilleux, I., Bendriss-Vermare, N., Bachelot, T., Goddard-Leon, S., Arfi, V., Biota, C., Doffin, A. C., Durand, I., Olive, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2360 · Cited by 758
Tran, D. Q., Ramsey, H., & Shevach, E. M. (2007) · Blood · doi:10.1182/blood-2007-06-094656 · Cited by 743
Maj, T., Wang, W., Crespo, J., Zhang, H., Wang, W., Wei, S., Zhao, L., Vatan, L., Shao, I., Szeliga, W., et al. (2017) · Nature Immunology · doi:10.1038/ni.3868 · Cited by 733 · cited 1×
“58 Through the multiple immunosuppressive mechanisms mentioned above, Tregs play a major role in resistance to PD-1 blockade therapy in many types of cancer.”
BackgroundDevelopment and Maintenance of Regulatory T cells
Ohkura, N., Kitagawa, Y., & Sakaguchi, S. (2013) · Immunity · doi:10.1016/j.immuni.2013.03.002 · Cited by 728
Onishi, Y., Fehervari, Z., Yamaguchi, T., & Sakaguchi, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711106105 · Cited by 716
Regulatory T cells in cancer immunotherapy
Nishikawa, H., & Sakaguchi, S. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.12.005 · Cited by 705
Self-citationRegulatory T Cells Exhibit Distinct Features in Human Breast Cancer
Plitas, G., Konopacki, C., Wu, K., Bos, P. D., Morrow, M., Putintseva, E. V., Chudakov, D. M., & Rudensky, A. Y. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.032 · Cited by 695
Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1
Ono, M., Yaguchi, H., Ohkura, N., Kitabayashi, I., Nagamura, Y., Nomura, T., Miyachi, Y., Tsukada, T., & Sakaguchi, S. (2007) · Nature · doi:10.1038/nature05673 · Cited by 690
De Simone, M., Arrigoni, A., Rossetti, G., Gruarin, P., Ranzani, V., Politano, C., Bonnal, R. J. P., Provasi, E., Sarnicola, M. L., Panzeri, I., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.021 · Cited by 687
Terme, M., Pernot, S., Marcheteau, E., Sandoval, F., Benhamouda, N., Colussi, O., Dubreuil, O., Carpentier, A. F., Tartour, E., & Taieb, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2325 · Cited by 684
CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors
Wang, H., Franco, F., Tsui, Y.-C., Xie, X., Trefny, M. P., Zappasodi, R., Mohmood, S. R., Fernández-García, J., Tsai, C.-H., Schulze, I., et al. (2020) · Nature Immunology · doi:10.1038/s41590-019-0589-5 · Cited by 672
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells
Gao, Y., Souza-Fonseca-Guimaraes, F., Bald, T., Ng, S. S., Young, A., Ngiow, S. F., Rautela, J., Straube, J., Waddell, N., Blake, S. J., et al. (2017) · Nature Immunology · doi:10.1038/ni.3800 · Cited by 654
Sugiyama, D., Nishikawa, H., Maeda, Y., Nishioka, M., Tanemura, A., Katayama, I., Ezoe, S., Kanakura, Y., Sato, E., Fukumori, Y., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1316796110 · Cited by 627
Self-citationFc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.010 · Cited by 592
Control of Regulatory T Cell Lineage Commitment and Maintenance
Josefowicz, S. Z., & Rudensky, A. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.009 · Cited by 571
Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion
Sawant, D. V., Yano, H., Chikina, M., Zhang, Q., Liao, M., Liu, C., Callahan, D. J., Sun, Z., Sun, T., Tabib, T., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0346-9 · Cited by 543
Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression
Gerriets, V. A., Kishton, R. J., Johnson, M. O., Cohen, S., Siska, P. J., Nichols, A. G., Warmoes, M. O., de Cubas, A. A., MacIver, N. J., Locasale, J. W., et al. (2016) · Nature Immunology · doi:10.1038/ni.3577 · Cited by 539
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
Ali, K., Soond, D. R., Piñeiro, R., Hagemann, T., Pearce, W., Lim, E. L., Bouabe, H., Scudamore, C. L., Hancox, T., Maecker, H., et al. (2014) · Nature · doi:10.1038/nature13444 · Cited by 529
Continuous requirement for the TCR in regulatory T cell function
Levine, A. G., Arvey, A., Jin, W., & Rudensky, A. Y. (2014) · Nature Immunology · doi:10.1038/ni.3004 · Cited by 521
Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine
Campesato, L. F., Budhu, S., Tchaicha, J., Weng, C.-H., Gigoux, M., Cohen, I. J., Redmond, D., Mangarin, L., Pourpe, S., Liu, C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17750-z · Cited by 516
Foxp3+ regulatory T cells: differentiation, specification, subphenotypes
Feuerer, M., Hill, J. A., Mathis, D., & Benoist, C. (2009) · Nature Immunology · doi:10.1038/ni.1760 · Cited by 507
Mitochondrial complex III is essential for suppressive function of regulatory T cells
Weinberg, S. E., Singer, B. D., Steinert, E. M., Martinez, C. A., Mehta, M. M., Martínez-Reyes, I., Gao, P., Helmin, K. A., Abdala-Valencia, H., Sena, L. A., et al. (2019) · Nature · doi:10.1038/s41586-018-0846-z · Cited by 494
Foxp3 Exploits a Pre-Existent Enhancer Landscape for Regulatory T Cell Lineage Specification
Samstein, R. M., Arvey, A., Josefowicz, S. Z., Peng, X., Reynolds, A., Sandstrom, R., Neph, S., Sabo, P., Kim, J. M., Liao, W., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.053 · Cited by 472
The Intersection between Tumor Angiogenesis and Immune Suppression
Rahma, O. E., & Hodi, F. S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1543 · Cited by 472
Tan, M. C. B., Goedegebuure, P. S., Belt, B. A., Flaherty, B., Sankpal, N., Gillanders, W. E., Eberlein, T. J., Hsieh, C.-S., & Linehan, D. C. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.3.1746 · Cited by 450
Lipid signalling enforces functional specialization of Treg cells in tumours
Lim, S. A., Wei, J., Nguyen, T.-L. M., Shi, H., Su, W., Palacios, G., Dhungana, Y., Chapman, N. M., Long, L., Saravia, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03235-6 · Cited by 426
Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
Serrels, A., Lund, T., Serrels, B., Byron, A., McPherson, R. C., von Kriegsheim, A., Gómez-Cuadrado, L., Canel, M., Muir, M., Ring, J. E., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.001 · Cited by 407 · cited 1×
“81 82 The specific cytokine and growth factor profile of the TME could induce the conversion of Tconvs to Tregs, which may contribute to the infiltration of Tregs into the TME.”
BackgroundOX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
Piconese, S., Valzasina, B., & Colombo, M. P. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071341 · Cited by 405
CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis
Stagg, J., Divisekera, U., Duret, H., Sparwasser, T., Teng, M. W. L., Darcy, P. K., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4246 · Cited by 401
Curti, A., Pandolfi, S., Valzasina, B., Aluigi, M., Isidori, A., Ferri, E., Salvestrini, V., Bonanno, G., Rutella, S., Durelli, I., et al. (2007) · Blood · doi:10.1182/blood-2006-07-036863 · Cited by 396
CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours
Zappasodi, R., Serganova, I., Cohen, I. J., Maeda, M., Shindo, M., Senbabaoglu, Y., Watson, M. J., Leftin, A., Maniyar, R., Verma, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03326-4 · Cited by 393
Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
Godin-Ethier, J., Hanafi, L.-A., Piccirillo, C. A., & Lapointe, R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1331 · Cited by 392
An evolutionary perspective on immunometabolism
Wang, A., Luan, H. H., & Medzhitov, R. (2019) · Science · doi:10.1126/science.aar3932 · Cited by 389
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
Sharma, A., Subudhi, S. K., Blando, J., Scutti, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0762 · Cited by 382
FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets
Saleh, R., & Elkord, E. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.022 · Cited by 352
Pacella, I., Procaccini, C., Focaccetti, C., Miacci, S., Timperi, E., Faicchia, D., Severa, M., Rizzo, F., Coccia, E. M., Bonacina, F., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720113115 · Cited by 344
Extracellular Adenosine-Mediated Modulation of Regulatory T Cells
Ohta, A., & Sitkovsky, M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00304 · Cited by 320
Continuous T Cell Receptor Signals Maintain a Functional Regulatory T Cell Pool
Vahl, J. C., Drees, C., Heger, K., Heink, S., Fischer, J. C., Nedjic, J., Ohkura, N., Morikawa, H., Poeck, H., Schallenberg, S., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.012 · Cited by 318
Sharma, A., Subudhi, S. K., Blando, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0402 · Cited by 312
Interleukin-35 Limits Anti-Tumor Immunity
Turnis, M. E., Sawant, D. V., Szymczak-Workman, A. L., Andrews, L. P., Delgoffe, G. M., Yano, H., Beres, A. J., Vogel, P., Workman, C. J., & Vignali, D. A. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.013 · Cited by 311
Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis
Lee, J. C., Mehdizadeh, S., Smith, J., Young, A., Mufazalov, I. A., Mowery, C. T., Daud, A., & Bluestone, J. A. (2020) · Science Immunology · doi:10.1126/sciimmunol.aba0759 · Cited by 308
Miska, J., Lee-Chang, C., Rashidi, A., Muroski, M. E., Chang, A. L., Lopez-Rosas, A., Zhang, P., Panek, W. K., Cordero, A., Han, Y., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.029 · Cited by 304
Ishida, T., Ishii, T., Inagaki, A., Yano, H., Komatsu, H., Iida, S., Inagaki, H., & Ueda, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0261 · Cited by 291
Sugiyama, E., Togashi, Y., Takeuchi, Y., Shinya, S., Tada, Y., Kataoka, K., Tane, K., Sato, E., Ishii, G., Goto, K., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aav3937 · Cited by 289
Self-citationSchenk, U., Frascoli, M., Proietti, M., Geffers, R., Traggiai, E., Buer, J., Ricordi, C., Westendorf, A. M., & Grassi, F. (2011) · Science Signaling · doi:10.1126/scisignal.2001270 · Cited by 286
Mechanisms of ATP Release by Inflammatory Cells
Dosch, M., Gerber, J., Jebbawi, F., & Beldi, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041222 · Cited by 283
Sun, X., Wu, Y., Gao, W., Enjyoji, K., Csizmadia, E., Müller, C. E., Murakami, T., & Robson, S. C. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.05.007 · Cited by 279
Gajewski, T. F., Corrales, L., Williams, J., Horton, B., Sivan, A., & Spranger, S. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-67577-0_2 · Cited by 278
Antitumour immunity regulated by aberrant ERBB family signalling
Kumagai, S., Koyama, S., & Nishikawa, H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00322-0 · Cited by 278
Self-citationRegulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis
Kishore, M., Cheung, K. C. P., Fu, H., Bonacina, F., Wang, G., Coe, D., Ward, E. J., Colamatteo, A., Jangani, M., Baragetti, A., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.10.017 · Cited by 276
Kumagai, S., Togashi, Y., Sakai, C., Kawazoe, A., Kawazu, M., Ueno, T., Sato, E., Kuwata, T., Kinoshita, T., Yamamoto, M., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.016 · Cited by 257
Self-citationCCR8+FOXp3+Tregcells as master drivers of immune regulation
Barsheshet, Y., Wildbaum, G., Levy, E., Vitenshtein, A., Akinseye, C., Griggs, J., Lira, S. A., & Karin, N. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1621280114 · Cited by 249
Kurose, K., Ohue, Y., Wada, H., Iida, S., Ishida, T., Kojima, T., Doi, T., Suzuki, S., Isobe, M., Funakoshi, T., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0357 · Cited by 241
Self-citationComito, G., Iscaro, A., Bacci, M., Morandi, A., Ippolito, L., Parri, M., Montagnani, I., Raspollini, M. R., Serni, S., Simeoni, L., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0688-7 · Cited by 241
Hermans, D., Gautam, S., García-Cañaveras, J. C., Gromer, D., Mitra, S., Spolski, R., Li, P., Christensen, S., Nguyen, R., Lin, J.-X., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1920413117 · Cited by 229
Foxp3 drives oxidative phosphorylation and protection from lipotoxicity
Howie, D., Cobbold, S. P., Adams, E., Ten Bokum, A., Necula, A. S., Zhang, W., Huang, H., Roberts, D. J., Thomas, B., Hester, S. S., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.89160 · Cited by 216
Tada, Y., Togashi, Y., Kotani, D., Kuwata, T., Sato, E., Kawazoe, A., Doi, T., Wada, H., Nishikawa, H., & Shitara, K. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0403-1 · Cited by 214
Self-citationZhou, G., & Levitsky, H. I. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2155 · Cited by 213
Sato, K., Sato, N., Xu, B., Nakamura, Y., Nagaya, T., Choyke, P. L., Hasegawa, Y., & Kobayashi, H. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6843 · Cited by 213
Takahata, Y., Nomura, A., Takada, H., Ohga, S., Furuno, K., Hikino, S., Nakayama, H., Sakaguchi, S., & Hara, T. (2004) · Experimental Hematology · doi:10.1016/j.exphem.2004.03.012 · Cited by 206
Immune checkpoint inhibitors: The linchpins of modern immunotherapy
Wilky, B. A. (2019) · Immunological Reviews · doi:10.1111/imr.12766 · Cited by 206
Van Damme, H., Dombrecht, B., Kiss, M., Roose, H., Allen, E., Van Overmeire, E., Kancheva, D., Martens, L., Murgaski, A., Bardet, P. M. R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001749 · Cited by 205
Solomon, I., Amann, M., Goubier, A., Arce Vargas, F., Zervas, D., Qing, C., Henry, J. Y., Ghorani, E., Akarca, A. U., Marafioti, T., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00133-0 · Cited by 204
Ahmadzadeh, M., Pasetto, A., Jia, L., Deniger, D. C., Stevanović, S., Robbins, P. F., & Rosenberg, S. A. (2019) · Science Immunology · doi:10.1126/sciimmunol.aao4310 · Cited by 201
Homeostatic control of metabolic and functional fitness of Treg cells by LKB1 signalling
Yang, K., Blanco, D. B., Neale, G., Vogel, P., Avila, J., Clish, C. B., Wu, C., Shrestha, S., Rankin, S., Long, L., et al. (2017) · Nature · doi:10.1038/nature23665 · Cited by 199
Identification of human CCR8 as a CCL18 receptor
Islam, S. A., Ling, M. F., Leung, J., Shreffler, W. G., & Luster, A. D. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130240 · Cited by 190
Aswad, F., Kawamura, H., & Dennert, G. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.5.3075 · Cited by 183
Ni, X., Jorgensen, J. L., Goswami, M., Challagundla, P., Decker, W. K., Kim, Y. H., & Duvic, M. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0830 · Cited by 167
Ji, D., Song, C., Li, Y., Xia, J., Wu, Y., Jia, J., Cui, X., Yu, S., & Gu, J. F. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000826 · Cited by 166
Doi, T., Muro, K., Ishii, H., Kato, T., Tsushima, T., Takenoyama, M., Oizumi, S., Gemmoto, K., Suna, H., Enokitani, K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1090 · Cited by 161
Self-citationMetabolic control of regulatory T cell (Treg) survival and function by Lkb1
He, N., Fan, W., Henriquez, B., Yu, R. T., Atkins, A. R., Liddle, C., Zheng, Y., Downes, M., & Evans, R. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1715363114 · Cited by 160
Duhen, R., Ballesteros‐Merino, C., Frye, A. K., Tran, E., Rajamanickam, V., Chang, S., Koguchi, Y., Bifulco, C. B., Bernard, B. M., Leidner, R. S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21383-1 · Cited by 156
Cuende, J., Liénart, S., Dedobbeleer, O., van der Woning, B., De Boeck, G., Stockis, J., Huygens, C., Colau, D., Somja, J., Delvenne, P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1983 · Cited by 155
Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models
Campbell, J. R., McDonald, B., Mesko, P. B., Siemers, N. O., Singh, P. B., Selby, M., Sproul, T. W., Korman, A. J., Vlach, L. M., Houser, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3585 · Cited by 151
Definition of target antigens for naturally occurring CD4+ CD25+ regulatory T cells
Nishikawa, H., Kato, T., Tawara, I., Saito, K., Ikeda, H., Kuribayashi, K., Allen, P. M., Schreiber, R. D., Sakaguchi, S., Old, L. J., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041959 · Cited by 130
Self-citationKvarnhammar, A. M., Veitonmäki, N., Hägerbrand, K., Dahlman, A., Smith, K. E., Fritzell, S., von Schantz, L., Thagesson, M., Werchau, D., Smedenfors, K., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0570-8 · Cited by 126
Differences in Tumor Regulatory T-Cell Localization and Activation Status Impact Patient Outcome
Ménétrier‐Caux, C., Gobert, M., & Caux, C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1642 · Cited by 125
Schuler, P. J., Harasymczuk, M., Schilling, B., Saze, Z., Strauss, L., Lang, S., Johnson, J. T., & Whiteside, T. L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0900 · Cited by 124
Flynn, M. J., Zammarchi, F., Tyrer, P. C., Akarca, A. U., Janghra, N., Britten, C. E., Havenith, C. E. G., Levy, J.-N., Tiberghien, A. C., Masterson, L. A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0233 · Cited by 124
Chen, Y., Haines, C. J., Gutcher, I., Hochweller, K., Blumenschein, W. M., McClanahan, T., Hämmerling, G., Li, M. O., Cua, D. J., & McGeachy, M. J. (2011) · Immunity · doi:10.1016/j.immuni.2011.02.011 · Cited by 123
Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis
Shabaneh, T. B., Molodtsov, A. K., Steinberg, S. M., Zhang, P., Torres, G. M., Mohamed, G. A., Boni, A., Curiel, T. J., Angeles, C. V., & Turk, M. J. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0365 · Cited by 120
Morris, A. B., Farley, C. R., Pinelli, D. F., Adams, L. E., Cragg, M. S., Boss, J. M., Scharer, C. D., Fribourg, M., Cravedi, P., Heeger, P. S., et al. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.006 · Cited by 118
Ahmad, S., Eid, R. A., Shrimali, R. K., Webb, M., Verma, V., Doroodchi, A., Berrong, Z., Samara, R. N., Rodríguez, P. C., Mkrtichyan, M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1839 · Cited by 110
Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells
Tanaka, A., Nishikawa, H., Noguchi, S., Sugiyama, D., Morikawa, H., Takeuchi, Y., Ha, D., Shigeta, N., Kitawaki, T., Maeda, Y., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191009 · Cited by 96 · cited 1×
“124 The PI3K signaling pathway is also essential for T cell survival and function.”
BackgroundSelf-citationRueda, C. M., Jackson, C. M., & Chougnet, C. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00216 · Cited by 82
Qu, Y., Zhang, B., Liu, S., Zhang, A., Wu, T., & Zhao, Y. X. (2010) · Cellular and Molecular Immunology · doi:10.1038/cmi.2010.45 · Cited by 74
Sukumar, S., Wilson, D. C., Yu, Y., Wong, J., Naravula, S., Ermakov, G., Riener, R. M., Bhagwat, B., Necheva, A. S., Grein, J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1439 · Cited by 62
調節性T細胞移動はグルコキナーゼ仲介される解糖に依存している【Powered by NICT】
Madhav, K., Kenneth, C. P. C., Hongmei, F., et al. (2017) · Immunity · Cited by 62
Sainson, R. C. A., Thotakura, A. K., Kosmač, M., Borhis, G., Parveen, N., Kimber, R., Carvalho, J. A., Henderson, S. J., Pryke, K. L., Okell, T., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0034 · Cited by 57
de Oliveira, C. E., Gasparoto, T. H., Pinheiro, C. R., Amôr, N. G., Nogueira, M. R. S., Kaneno, R., Garlet, G. P., Lara, V. S., Silva, J. S., Cavassani, K. A., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0341 · Cited by 51
Lim, W. C., Olding, M., Healy, E., & Millar, T. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00565 · Cited by 50
Qinfeng, S., Wang, D., Xiaofeng, Y., Shah, W., Hongwei, C., & Yili, W. (2013) · Radiation Research · doi:10.1667/rr3155.1 · Cited by 45
Edwards, J. P., Hand, T. W., da Fonseca, D. M., Glass, D. D., Belkaid, Y., & Shevach, E. M. (2016) · European Journal of Immunology · doi:10.1002/eji.201546204 · Cited by 44
Luke, J. J., Zha, Y., Matijevich, K., & Gajewski, T. F. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0140-2 · Cited by 31
発癌性変化は調節性T細胞への代謝優位性を与えることにより腫瘍進行を促進する微小環境を創造する【JST・京大機械翻訳】
Shogo, K., Yosuke, T., Chika, S., Kawazoe, A., Kawazu, M., Ueno, T., Sato, E., Kuwata, T., Takahiro, K., Yamamoto, M., et al. (2020) · Immunity · Cited by 17
Self-citationPeña, L. M.-P., Pérez-Santos, M., Camacho, I. H., Bandala, C., & Anaya-Ruíz, M. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1732352 · Cited by 9
Martín, Á. G., Leis, O., Gumuzio, J., Prieto, I., & Ruiz, E. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-5038 · Cited by 7
Cited by
Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
Pei, L., Liu, Y., Liu, L., Gao, S., Gao, X., Feng, Y., Sun, Z., Zhang, Y., & Wang, C. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01731-z · Cited by 257
Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review
Li, Y., Zhang, C., Jiang, A., Lin, A., Liu, Z., Cheng, X., Wang, W., Cheng, Q., Zhang, J., Wei, T., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05104-y · Cited by 105
“…chemicals such tumor antigens, IL-2, IL-10, TGF-β, and other soluble molecules that stimulate the T-cell receptor (TCR) and enhance the transformation of naive CD4 + T-cells into iTregs [28]. iTregs are the main kind of Tregs that enter tumors, despite the presence of both tTregs and iTregs.”
Background
Metadata
- Authors
- Koyama, S., & Nishikawa, H.
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2021-07
- Volume
- 9
- Issue
- 7
- Pages
- e002591
- ISSN
- 2051-1426 (ISSN-L)
- OpenAlex
- W3185231871
- Cited by
- 305
- References
- 142
- FWCI
- 16.63
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-09-13)
- Open access
- gold
- Funders
- Japan Science and Technology Agency (17H06162, 21K07252)
- Japan Agency for Medical Research and Development (16cm0106301h0001, 19ae0101074s0401, 19cm0106335h0002)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.